RxDoctor Payments Data

Samar Alsharif

Hospitalist · Knoxville, TNNPI 1528032984

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $290, more than ten times the $24 reported in 2019.

$856in general payments, 2019–2025

Across 35 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$165
  • AbbVie$155
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$97
  • AstraZeneca$94
  • Pfizer$76
  • Mallinckrodt Hospital Products Inc.$64
  • plus $205 from 9 others

What the payments were for

  • Food & beverage$856100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$856 in reported general payments places this provider in the 85th percentile of 349 hospitalist providers in Tennessee.

See all hospitalist providers in Tennessee

Medicare billing

Part B allowed, 2024
$133,579
Medicare patients
230
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban25$22,269
SymbicortBudesonide/Formoterol Fumarate13$2,814
Cefdinir80$1,056
Pantoprazole Sodium60$614
Albuterol Sulfate HfaAlbuterol Sulfate18$533
Zonisamide11$438
Doxycycline Hyclate50$374
Methylprednisolone36$282
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19$109
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$103
Topiramate11$89
Atorvastatin Calcium21$85
ClopidogrelClopidogrel Bisulfate15$82
Valsartan11$81
Gabapentin12$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$22,26925 claims
AstraZenecaSymbicort$94$2,81413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 349 hospitalist providers in Tennessee.

Other hospitalist in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →